ALLOGENE THERAPEUTICS INC (ALLO)
Health Care · Allogeneic CAR-T cell immunotherapy · NASDAQ
Clinical-stage immunotherapy company developing off-the-shelf allogeneic CAR-T cell therapies for cancer and autoimmune diseases.
What ALLOGENE THERAPEUTICS INC does
Allogene Therapeutics is a clinical-stage immuno-oncology company pioneering genetically engineered allogeneic (donor-derived) T cell product candidates for cancer and autoimmune diseases. Unlike autologous therapies that use a patient's own cells, Allogene's approach uses healthy donor T cells engineered to be "off-the-shelf" products available to any patient, aiming to deliver treatments faster, more reliably, and at greater scale. The company uses gene-editing technologies (TALEN and CRISPR) to minimize graft-versus-host disease risk and employs its proprietary Dagger® technology to enhance CAR-T cell expansion and persistence.
Themes: ["Allogeneic CAR-T immunotherapy","Large B-cell lymphoma (LBCL)","Renal cell carcinoma (RCC)","Autoimmune disease treatment","Gene-edited cell therapy","Off-the-shelf oncology"]
Fundamentals
- Price$2.10 as of 2026-07-09 close
- Market cap$716M as of 2026-07-10
- 1-year return+76.7% as of 2026-07-09 close
- Net margin-269835.0% as of 2026-07-10
- ROE-57.1% as of 2026-07-10
- Debt / equity0.00 as of 2026-07-10
- Beta0.45 as of 2026-07-10
Key risks (from latest filing)
["Clinical development risk: Company is clinical-stage with no approved products; multiple anticipated readouts in Q2 2026 are critical to validate key scientific assumptions about off-the-shelf CAR-T safety and efficacy.","Manufacturing and scalability risk: Success depends on building and maintaining state-of-the-art cGMP manufacturing capabilities; a death attributed to disseminated adenovirus infection in the FCA arm of ALPHA3 has already prompted changes to the trial protocol.","Allogeneic rejection risk: Allogeneic T cell therapies face inherent biological challenges including graft-versus-host disease and host-mediated rejection, which the company attempts to address through gene editing and Dagger® technology but remain unproven at commercial scale."]
Fundamentals: Finnhub, as of 2026-07-10. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-09.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date.